Pfizer Inc. (NYSE:PFE) Shares Sold by EP Wealth Advisors LLC

EP Wealth Advisors LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 0.2% in the second quarter, Holdings Channel reports. The institutional investor owned 335,241 shares of the biopharmaceutical company’s stock after selling 821 shares during the quarter. EP Wealth Advisors LLC’s holdings in Pfizer were worth $9,380,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Brandes Investment Partners LP increased its stake in Pfizer by 10.2% during the second quarter. Brandes Investment Partners LP now owns 5,573,282 shares of the biopharmaceutical company’s stock worth $155,871,000 after acquiring an additional 516,714 shares during the last quarter. Kimelman & Baird LLC acquired a new stake in shares of Pfizer during the 2nd quarter worth about $1,313,000. B. Riley Wealth Advisors Inc. raised its holdings in Pfizer by 11.4% in the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 365,151 shares of the biopharmaceutical company’s stock valued at $10,217,000 after buying an additional 37,455 shares during the period. Wallace Capital Management Inc. lifted its position in Pfizer by 7.4% in the second quarter. Wallace Capital Management Inc. now owns 10,190 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 700 shares during the last quarter. Finally, Regal Investment Advisors LLC boosted its stake in Pfizer by 7.3% during the second quarter. Regal Investment Advisors LLC now owns 282,398 shares of the biopharmaceutical company’s stock worth $7,901,000 after buying an additional 19,091 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on PFE. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Barclays raised their price target on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, UBS Group increased their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Stock Down 0.5 %

Shares of NYSE:PFE opened at $28.94 on Tuesday. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $34.11. The firm’s 50 day moving average price is $29.29 and its 200 day moving average price is $28.30. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The stock has a market cap of $163.96 billion, a price-to-earnings ratio of -482.25, a price-to-earnings-growth ratio of 1.27 and a beta of 0.68.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.67 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.